Combinatorial ligand design targeted at protein families

Journal of Chemical Information and Modeling

Volumn 45, Issue 2, 2005, Pages 314-320

  Todorov, Nikolay P ^a   Buenemann, Christoph L ^b   Alberts, Ian L ^a  

^a De Novo Pharmaceuticals Ltd   (United Kingdom)

^b Novartis Institutes for Biomedical Research Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEXATION; COMPUTATIONAL METHODS; CONFORMATIONS; CRYSTAL STRUCTURE; DRUG PRODUCTS; PROTEINS;

CELL CYCLES; DRUG DESIGN; LIGANDS; SPECSCORE RANKING;

MOLECULAR STRUCTURE;

CYCLIN DEPENDENT KINASE; LIGAND;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; COMBINATORIAL CHEMISTRY; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLIN-DEPENDENT KINASES; LIGANDS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 18344392489     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci049692r     Document Type: Article

References (34)

1. Gadek, T. R.; Nicholas, J. B. Small molecule antagonists of proteins. Biochem. Phamacol. 2003, 65, 1-8.
2. Waszkowycz, B. Structure-based approaches to drug design and virtual screening. Curr. Opin. Drug Discovery Dev. 2002, 5, 407-413.
3. Lyne, P. D. Structure-based virtual screening: an overview. Drug Discovery Today 2002, 7, 1047-1055.
4. Marrone, T. J.; Briggs, J. M.; McCammon, J. A. Structure-based drug design: Computational advances. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 71-90.
5. Bissantz, C.; Folkers, G.; Roganan, D. Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J. Med. Chem. 2000, 43, 4759-4763.
6. Lamb, M. L.; Burdick, K. W.; Toba, S.; Young, M. M.; Skillman, A. G.; Zou X.; Arnold, J. R.; Kuntz, I. D. Design, docking, and evaluation of multiple libraries against multiple targets. Proteins 2001, 42, 296-318.
7. Janin, J. Quantifying biological specificity: the statistical mechanics of molecular recognition. Proteins 1996, 25, 438-445.
8. Sims, P. A.; Wong, C. F.; McCammon, J. A. A. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors. J. Med. Chem. 2003, 46, 3314-3325.
9. Kastenholz, M. A.; Pastor, M.; Cruciani, G.; Haaksma E. E. J.; Fox, T. GRID/CPCA: A new computational tool to design selective ligands. J. Med. Chem. 2000, 43, 3033-3044.
10. Ridderstrom, M.; Zamora, I.; Fjellstrom, O.; Andersson, T. B. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18 and 2C19 homology models using GRID/CPCA. J. Med. Chem. 2001, 44, 4072-4081.
11. Baskin, I. I.; Tikhonova, I. G.; Palyulin, V. A.; Zefirov, N. S. Selectivity fields: comparative molecular field analysis (CoMFA) of the glycine/NMDA and AMPA receptors. J. Med. Chem. 2003, 46, 4063-4069.
12. Kangas, E.; Tidor, B. Electrostatic specificity in molecular ligand design. J. Chem. Phys. 2000, 112, 9120-9131.
13. Greenbaum, D. C.; Arnold, W. D.; Lu, F.; Hayrapetian, L.; Baruch, A.; Krumrine, J.; Toba, S.; Chehade, K.; Brömme, D.; Kuntz, I. D. Small molecule affinity fingerprinting: a tool for enzyme family subclassification, target identification, and inhibitor design. Chem., Biol. 2002, 9, 1085-1094.
14. Vigers, G. P.; Rizzi, J. Multiple active site corrections for docking and virtual screening. J. Med. Chem. 2004, 47, 80-89.
15. Knockaert, M.; Greengard, P.; Meijer, L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 2002, 23, 417-425.
16. Morgan, D. O. Principles of CDK regulation. Nature 1995, 374, 131-134.
17. Pavletich, N. P. Mechanisms of cyclin-dependent kinase regulation: Structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J. Mol. Biol. 1999, 287, 821-828.
18. Russell, R. B.; Barton, G. J. Multiple protein-sequence alignment from tertiary structure comparison - asignment of global and residue confidence levels. Proteins 1992, 14, 309-323.
19. Todorov, N. P.; Dean, P. M. Evaluation of a method for controlling molecular scaffold diversity in de novo ligand design. J. Comput.-Aided Mol. Des. 1997, 11, 175-192.
20. Todorov, N. P.; Dean, P. M. Computational ligand design by free energy minimization. In Biological Phisics; Frauenfelder, H., Hummer, G., Garcia, R., Eds.; American Institute of Physics: 1999.
21. Stahl, M.; Todorov, N. P.; James, T.; Mauser, H.; Boehm, H.-J.; Dean, P. M. A validation study on the practical use of automated de novo design. J. Comput.-Aided Mol. Des. 2002, 16, 459-478.
22. Stahl, M.; Rarey, M. Detailed analysis of scoring fucntions for virtual screening. J. Med. Chem. 2001, 44, 1035-1042
23. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP - Retrosynthetic combinatorial analysis procedure: A powerful new technique for identifying priviledged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci. 1998, 38, 511-522.
24. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002.
25. Shewchuk, L.; Hassell, A.; Wisely, B.; Rocque, W.; Holmes, W.; Veal, J.; Kuyper, L. F. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilino-quinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J. Med. Chem. 2000, 43, 133-138.
26. Jeffrey, P. D.; Russo, A. A.; Polyak, K.; Gibbs, A.; Hurwitz, J.; Massague, J.; Pavletich, N. P. Mechanism of CDK activation revealed by the structure of a cyclin A- CDK2 complex. Nature 1995, 376, 313-320.
27. Schulze-Gahmen, U.; Brandsen, J.; Jones, H. J.; Morgan, D. O.; Meijer, - L.; Vesely, J.; Kim, S. H. Multiple modes of ligand recognition - crystal structures of cyclin-dependent-protein-kinase-2 in complex with ATP and 2 inhibitors, olomoucine and isopentenyladenine. Proteins 1995, 22, 378-391.
28. Tarricone, C.; Dhavan, R.; Peng, J.; Areces, L. B.; Tsai, L. H.; Musacchio, A. Structure and regulation of the CDK5-p25(nck5a) complex. Mol. Cell 2001, 8, 657-669.
29. Brotherton, D. H.; Dhanaraj, V.; Wick, S.; Brizuela, L.; Domaille, P. J.; Volyanik, E.; Xu, X.; Parisini, E.; Smith, B. O.; Archer, S. J.; Serrano, L.; Brenner, S. L.; Blundell, T. L.; Laue, E. D. Crystal structure of the complex of the cyclin D dependent kinase Cdk6 bound to the cell-cycle inhibitor p19(INK4d). Nature 1998, 395, 244-250.
30. Schulze-Gahmen, U.; Kim, S. H. Structural basis for CDK6 activation by a virus-encoded cyclin. Nature Struct. Biol. 2002, 9, 177-181.
31. Insight II is aproduct of Accelrys Inc.
32. Daylight Chemical Information System Inc., http://www.daylight.com/
33. Humphrey, W.; Dalke, A.; Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 1996, 14, 33-38.
34. http://jedi.ks.uiuc.edu/~johns/raytracer